We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 14 million in the U.S.
May 08, 2020 Lyra Therapeutics to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference
May 05, 2020 Lyra Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
